How Quickly Does Aimovig Start Reducing Migraine Days?
Aimovig (erenumab) reduces monthly migraine days in many patients within the first month of treatment. In clinical trials, patients with episodic migraine (4-14 headache days per month) saw an average reduction of 3.7 fewer migraine days per month after one month, compared to 2.2 for placebo.[1] About 40-50% of patients achieved at least a 50% reduction in migraine days by month one.[1][2]
For chronic migraine (15+ headache days per month), reductions were smaller initially—around 2 fewer days after one month—but improved over time.[2]
What Do Patients Experience in the First Few Months?
- Month 1: Noticeable drop for responders; some report fewer severe attacks within 1-2 weeks, though full effects build gradually.
- Months 2-3: Average reductions stabilize at 4-6 fewer migraine days per month for episodic cases, with 30-40% seeing 75%+ improvement.[1][3]
- By Month 3: FDA approval data shows sustained benefits; non-responders may discontinue as effects plateau.[2]
Individual results vary based on migraine type, prior treatments, and adherence. Aimovig is self-injected monthly, so consistent use is key.
Who Responds Fastest and Why?
Patients new to preventive therapies or those with moderate episodic migraines often see quicker reductions. CGRP blockers like Aimovig target migraine pathways directly, explaining the rapid onset versus older drugs (e.g., topiramate takes 2-3 months).[3] Factors slowing response include severe chronic migraine or medication overuse.
How Does Aimovig Compare to Emgality or Nurtec?
| Drug | Time to 50% Migraine Reduction | Avg. Monthly Day Reduction (Month 1) |
|------|--------------------------------|--------------------------------------|
| Aimovig | ~40% by month 1 [1] | 3.7 days |
| Emgality (galcanezumab) | ~30-40% by month 1 [4] | 4.8 days |
| Nurtec (rimegepant, acute) | Hours for single attacks [5] | N/A (not preventive) |
Aimovig matches peers in speed but has a fixed monthly dose, unlike weekly options.
What If It Doesn't Work After a Few Months?
Up to 30-40% don't achieve significant reduction by month 3; guidelines recommend reassessing then.[3] No Aimovig-specific patents block generics yet—U.S. exclusivity ends around 2029, with challenges possible earlier.[6] Switching to another CGRP like Ajovy may help.
Switch to oral gepants (e.g., Qulipta) if injections fail.
[1]: FDA Aimovig Label
[2]: NEJM Phase 3 Trial (2017)
[3]: American Headache Society Guidelines
[4]: FDA Emgality Label
[5]: FDA Nurtec ODT Label
[6]: DrugPatentWatch: Aimovig Patents